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CASE REPORT
AMERICAN CUTANEOUS LEISHMANIASIS WITH UNUSUAL CLINICAL PRESENTATION AND 
RESPONSE TO TREATMENT
Andrea Claudia Bekner Silva FERNANDES(1), Raíssa Bocchi PEDROSO(1), Eneide Aparecida Sabaini VENAZZI(2), Paulo Donizeti ZANZARINI(2),  
Sandra Mara Alessi ARISTIDES(2), Maria Valdrinez Campana LONARDONI(2), & Thaís Gomes Verzignassi SILVEIRA(2)
SUMMARY
The clinical manifestations and prognosis of cutaneous leishmaniasis (CL) can be influenced by the immune response of the 
patient and the species of the parasite. A case of atypical clinical presentation of CL, with development of non-characteristic lesions, 
poor response to therapy, and a long time to resolution is reported. Confirmatory laboratory tests included parasite detection, indirect 
immunofluorescence, Montenegro skin test, polymerase chain reaction, and parasite identification by multilocus enzyme electrophoresis. 
The parasite was identified as Leishmania braziliensis. The lesion was unresponsive to three complete courses of N-methylglucamine 
antimoniate intramuscular, and to treatment with pentamidine. The patient did not tolerate amphotericin B. The lesion finally receded 
after treatment with intravenous N-methylglucamine antimoniate. It is essential to ensure the accuracy of diagnosis and the appropriate 
treatment, which can include the use a second choice drug or a different route of administration.
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INTRODUCTION
American cutaneous leishmaniasis (ACL) is a major public health 
problem in the New World. Clinical presentation and outcome of ACL are 
associated with the host immune response and the infecting Leishmania 
specie1. In Brazil, cutaneous leishmaniasis (CL), mainly caused by 
Leishmania (Viannia) braziliensis, is one of the dermatological diseases 
that deserves more attention due to its magnitude, as well as the risk of 
deformities and psychological involvement2. 
The most common clinical form is the classical ulcer, with an 
indurate raised outer border and sharply incised central crater that usually 
self-heals over a period of months. The usual clinical presentations of 
leishmaniasis are easily diagnosed by clinicians in endemic regions, 
but unusual forms may give rise to difficulties in the diagnosis and 
appropriate treatment2. Cutaneous leishmaniasis can produce a large 
variety of atypical and rare forms. There has been an increase in the 
number of papers reporting unusual clinical presentations, both for the 
Old and the New World3,4,5,6,7,8,9.
Meglumine antimoniate is considered the first choice drug for CL 
treatment in Brazil. The Ministry of Health recommends 10–20 mg/kg 
Sb5+ per day for a period of 20 days, by intravenous or intramuscular 
route. If no remission is observed, a new treatment cycle is administered 
for 30 days. In the absence of therapeutic response, the second choice 
drugs, amphotericin B or pentamidine, are used2. Despite pentavalent 
antimonials (Sb5+) be considered first-line drugs used to treat CL caused 
by different species, an increase in treatment failure has been documented 
in several regions of the world10.
We report a case of a patient with an unusual clinical form of 
cutaneous leishmaniasis with poor response to antimonial therapy and 
development of non-characteristic lesions. The present study received 
approval from the Permanent Committee for Ethics in Research involving 
Humans (Process No. 533/2009) of the Universidade Estadual de 
Maringá. The patient agreed to participate in the study and signed a free 
informed consent form. Written consent was obtained from the patient 
and his wife for this publication.
CASE REPORT
A forty-five-year-old black male patient from Apucarana, Paraná, 
with one atypical lesion on the right side of his back was attended, 
in March 2009, in the LEPAC (Laboratório de Ensino e Pesquisa 
em Análises Clínicas) of the Universidade Estadual de Maringá, 
for cutaneous leishmaniasis (CL) laboratory diagnosis. The patient 
Fernandes ACBS, Pedroso RB, Venazzi EAS, Zanzarini PD, Aristides SMA, Lonardoni MVC, Silveira TGV. American cutaneous leishmaniasis with unusual clinical presentation and response 
to treatment. Rev Inst Med Trop Sao Paulo. 2016;58:20.
Page 2 of 4
reported that the lesion had been present for approximately one month 
(Fig. 1A). The lesion was a rounded plaque, with a erythematous 
violaceous center, descamative ulcerated edges, surrounded by an 
extensive area of lichenification, measuring 20 cm. Based on clinical 
appearance, the differential diagnosis of the lesion included chronic 
simple lichen, psoriasis, squamous cell carcinoma, chromomycosis, 
cutaneous tuberculosis, syphilis, paracoccidioidomycosis, and 
sarcoidosis. Before seeking for medical attention, the patient used 
topical antibiotics, but the lesion persisted without improvement. The 
performed tests showed a positive Montenegro skin test (MST) with an 
induration of 10 mm and indirect immunofluorescence (IIF) positive 
for anti-Leishmania IgG antibodies, reaching a titer of 80. Leishmania 
amastigotes were detected in the material obtained by scraping of 
the lesion stained by Giemsa (Fig. 1B) and cultured in blood base 
agar (BBA). The BBA grown parasites were sent to the Coleção de 
Leishmania of Instituto Oswaldo Cruz (CLIOC), Rio de Janeiro, Brazil, 
for identification and the strains were confirmed as L. (V.) braziliensis 
(MHOM/BR/2009/3476). The species identification was performed by 
multilocus enzyme electrophoresis (MLEE). To exclude the possibility 
of coexisting infections, fungi and HIV investigations were performed 
with negative results. 
The patient was treated with 120 ampoules of intramuscular 
meglumine antimoniate (approximately 15 mg/kg Sb5+ per day) in three 
cycles of 20 days each at the Pronto Atendimento Municipal of Apucarana 
municipality. Approximately 40 days after the end of treatment (August 
2009) the lesion was still active and new laboratory tests were performed. 
The IIF test was positive with a titer of 160 and the direct parasite search 
was negative. 
About six months later (May 2010) the patient was submitted to 
another treatment with intravenous pentamidine (4 mg/kg per day) for 
seven days, which resulted in apparent healing of the lesion. In June 
2010, the values of serum amylase (87 U/L) and creatinine (1.0 mg/
dL) were normal. However, some months later, new papular lesions 
emerged, ulcerated and spread to the axillary region. In November 
2010, the patient was admitted for treatment with amphotericin B 
desoxycholate (50 mg/day). The treatment was discontinued after three 
doses because the values of serum urea (88 mg/dL) and creatinine (3.1 
mg/dL) were increased indicating renal failure. One additional course 
of pentamidine for 10 days was established (April 2011). There was 
a partial clinical resolution of lesions with the patient still presenting 
some residual lesions. 
In February 2012, about three years after the onset of the lesion and 
despite the multiple treatments, the lesion was not healing. The lesion 
was an ulcerated plaque with erythematous fibrous bottom and verrucous 
edges, surrounded by a lichenification area in the right scapular region 
and posterior region of the right arm (Fig. 1C). New laboratory tests 
were performed. The direct parasite search revealed the presence of 
characteristic amastigotes of Leishmania spp., the IIF showed titer 320, 
and the polymerase chain reaction (PCR) for kDNA minicircles of the 
subgenus Leishmania (Viannia) was positive.
The patient was treated again with meglumine antimoniate by the 
intravenous route (3 ampoules per day) for approximately 40 days. 
Following this treatment, the lesion healed. Unfortunately, about a year 
after the end of the treatment, the patient died of a heart attack.
DISCUSSION
This report describes an unusual case of CL due to the clinical 
presentation. There was the development of non-characteristic lesions, 
poor response to therapy and a long time to resolution. The patient was 
referred to laboratorial diagnosis of CL because, although he lived in 
an urban area, he had worked in a rural area, near a dam in an endemic 
Fig. 1 - (A) Initial lesion (one-month-old) on the right back of the patient. (B) Positive direct 
parasite search with characteristic amastigotes (arrow). (C) The lesion after meglumine 
antimoniate (120 ampoules), pentamidine, and amphotericin B treatments.
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region of CL. According to the patient, the lesion had been present for 
approximately one month despite presenting 20 cm. 
Laboratory diagnosis confirmed the clinical suspicion of CL, with 
positive results in the direct search of parasites, with few amastigotes in 
the examined slides, presence of IgG antibodies and positive MST. The 
antibody search tests are sensitive and specific, but they are associated to 
cross-reactivity with other diseases, mainly Chagas disease and visceral 
leishmaniasis2,11. MST does not differentiate current and past disease 
(most often remains positive after treatment) and does not distinguish 
between infection and disease. MST presents an estimated 84% positivity 
in the cutaneous form of CL11.
In the New World, about fifteen species of Leishmania were found in 
humans causing CL12. The three main species causing CL in Brazil are L. 
(V.) braziliensis, L. (V.) guyanensis and L. (L.) amazonensis2. According 
to WHO, the CL clinical forms include localized, disseminated, diffuse, 
and atypical cutaneous and mucocutaneous leishmaniases12. Many factors 
can influence the clinical manifestations and prognosis of leishmaniasis, 
such as the immune response of the patient and the species of the 
parasite1,13. The parasite was identified as L. (V.) braziliensis, a prevalent 
species in southern Brazil and widely distributed in the country2. This 
species can induce a wide spectrum of clinical and immunopathological 
manifestations14. 
Atypical lesions of cutaneous leishmaniasis caused by different 
species of Leishmania has been reported. ADRIANO et al.3 reported a 
case of an unusual presentation of American tegumentary leishmaniasis 
involving a solitary lesion on the ear lobe, without ulceration. 
CALPOVINA et al.4 described three distinct variants of CL (erysipeloid, 
recidiva cutis (LRC), and disseminated leishmaniasis (DL) in children, 
caused by L. (V.) panamensis. TURETZ et al.15 described patients with 
disseminated leishmaniasis of acneiform, papular, nodular, and ulcerated 
types, caused by L. (V.) braziliensis. NEITZKE-ABREU et al.16 have 
also reported a case of CL with atypical clinical manifestations due to 
L. (V.) braziliensis. SANDOVAL-JUAREZ et al.9 described an unusual 
clinical manifestation of CL caused by L. amazonensis, in a child that 
was treated with antimony, had partial remission of some lesions, and 
reactivation of the lesions following a chronic course. 
In the case reported in the present study, the lesion was an atypical 
clinical form and was still active after three cycles of meglumine 
antimoniate administered intramuscularly. The peculiarity of this case 
of leishmaniasis with lesion in form of rounded plaque, descamative 
ulcerated edges, erythematous violaceous center, and presenting an 
extensive area of lichenification around the lesion, are uncommon clinical 
manifestations in CL.
In atypical cases of CL, it is important to rule out the possibility of 
co-infections. CL in AIDS patients in the New World shows multiple, 
polymorphic and relapsing lesions12. In this case, co-infection with HIV 
was discarded, thereby to fungal infection.
Despite the apparent healing after treatment with intravenous 
pentamidine, new papular lesions emerged, ulcerated and spread to 
the axillary region. The patient was treated with amphotericin B. The 
treatment was discontinued because the patient showed alterations 
in renal function tests. An additional course of pentamidine was 
administered, there was a partial clinical resolution of lesions, but some 
residual lesions remained. About nine months after, the lesion was 
an ulcerated plaque, reaching the right scapular region and posterior 
region of the right arm. Since there was no successful treatment 
with second-line drugs available, meglumine antimoniate was used 
again, but intravenously. Although there is no difference between the 
intramuscular and intravenous routes, as regards the efficacy and safety 
of the drug3, the lesion finally receded after treatment with meglumine 
antimoniate administered intravenously. 
Despite pentavalent antimonials (Sb5+) being considered first-line 
drugs used to treat CL caused by different species, an increase in treatment 
failure has been documented in several regions of the world4. Studies 
conducted in Latin America have reported failure in CL treatment with 
this drug: 7% in Bolivia17, 16% in Brazil1, and up to 39% in Colombia18. 
GUIMARÃES et al.19 described two cases of atypical ACL that healed 
after three courses of antimony (15-20 mg/kg/day intravenously for 20 
days) and 13 cases healed with amphotericin B, after failure of three 
or more courses of antimony. PIMENTEL et al.20 reported a similar 
case of cutaneous leishmaniasis where the lesion relapsed following 
two systemic treatments with meglumine antimoniate. The patient was 
treated with amphotericin B, which was interrupted due to poor tolerance. 
Afterwards, the patient was submitted to intramuscular pentamidine, and 
no relapse was observed.
An atypical clinical form of CL with a difficult treatment response 
and a long time to resolution was the main contribution of this study. 
Reports of unusual and rare clinical forms of CL are relevant to 
physicians and researchers finding out what Leishmania species 
are capable of, causing forms of difficult diagnosis and treatment. 
Moreover, the knowledge of these cases is essential to ensure the 
accuracy of diagnosis and the appropriate treatment of the patient, 
which can include the use a second-line drug or a different route of 
administration for the first-line drug.
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